PTC Therapeutics (PTCT) Is Down 11.5% After Raising 2026 Outlook And Boosting Profitability - Has The Bull Case Changed?

PTC Therapeutics reported strong Q2 2026 revenue of US$360.52 million and net income of US$83.5 million, leading to an increased full-year 2026 revenue outlook of US$1.18 billion to US$1.28 billion. Despite this positive financial report, the company's shares experienced an 11.47% weekly decline, prompting questions about the sustainability of its newfound profitability given lower year-to-date revenue compared to the previous year. The article suggests that while profitability improved, the stock might still be overvalued, and investors should scrutinize the evolving business mix and earnings quality.